ClinicalTrials.Veeva

Menu
V

Vanderbilt University Medical Center | Vanderbilt - Ingram Cancer Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
ASTX727
Daratumumab
Teclistamab
TTI-101
Pomalidomide
Azacitidine
Talquetamab
Nab-Paclitaxel
Vinorelbine

Parent organization

This site is a part of Vanderbilt University Medical Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 20 total trials

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho...

Invitation-only
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Drug: ASTX727

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of a...

Enrolling
Advanced or Metastatic Colorectal Cancer
Biological: Leucovorin
Biological: Fluorouracil

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and t...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Daratumumab

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the...

Active, not recruiting
Relapsed/ Refractory Multiple Myeloma
Drug: PD-1 Inhibitor
Drug: Talquetamab

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with p...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Teclistamab

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:* Participants rec...

Enrolling
Beta-thalassemia
Myelodysplastic Syndromes (MDS)
Drug: Luspatercept

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carci...

Active, not recruiting
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Drug: Cisplatin/Carboplatin; 5FU
Drug: pembrolizumab

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Active, not recruiting
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Drug: evorpacept
Drug: pembrolizumab

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase...

Active, not recruiting
Cancer
Drug: cetuximab
Drug: TTX-080

Trial sponsors

Janssen (J&J Innovative Medicine) logo
A
Astex Pharmaceuticals logo
H. Lee Moffitt Cancer Center and Research Institute logo
A
Arcus Biosciences logo
Celgene logo
C
D
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems